Guggenheim Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $15
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Yatin Suneja initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $15.
Guggenheim analyst Yatin Suneja initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $15.